Reveals marked platelet reduction and hypercoagulability following heparin exposure, highlighting the necessity of prompt therapeutic-dose anticoagulation.
HIT is characterized by a platelet-count fall of more than 50% at 5 to 10 days after the start of heparin and hypercoagulability. Platelet factor 4–heparin antibody testing has a high negative, but low positive, predictive value. Treatment involves therapeutic-dose anticoagulation.
No takes yet. Share an insight, caveat, or question.
Andreas Greinacher (2015) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: